Related references
Note: Only part of the references are listed.Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy
Masanori Noguchi et al.
CLINICAL CANCER RESEARCH (2016)
Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer
Yukiko Tabuchi et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain
Keith L. Knutson et al.
CANCER RESEARCH (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer
Kazuhiro Yoshimura et al.
EUROPEAN UROLOGY (2016)
Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition
Barbara Melosky et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Xiaojun Liu et al.
CANCER RESEARCH (2015)
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
Hillary G. Caruso et al.
CANCER RESEARCH (2015)
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
Keiichi Ota et al.
CLINICAL CANCER RESEARCH (2015)
Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma
Cheng Lin et al.
CLINICAL LUNG CANCER (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
Chee-Seng Tan et al.
LANCET ONCOLOGY (2015)
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Wendy A. Cooper et al.
LUNG CANCER (2015)
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
James Schuster et al.
NEURO-ONCOLOGY (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma
Laura A. Johnson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
Yanna Tang et al.
ONCOTARGET (2015)
STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients
Raghvendra M. Srivastava et al.
CANCER IMMUNOLOGY RESEARCH (2015)
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
A. D'Incecco et al.
BRITISH JOURNAL OF CANCER (2015)
A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
Kazuya Ofuji et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
Endogenous antibody responsiveness to epidermal growth factor receptor is associated with immunoglobulin allotypes and overall survival of patients with glioblastoma
Janardan P. Pandey et al.
NEURO-ONCOLOGY (2015)
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
Jianfeng Han et al.
SCIENTIFIC REPORTS (2015)
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer
K. Azuma et al.
ANNALS OF ONCOLOGY (2014)
Personalized Peptide Vaccine for Treatment of Advanced Cancer
Tetsuro Sasada et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
Ching-Yao Yang et al.
EUROPEAN JOURNAL OF CANCER (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
Koichi Azuma et al.
PLOS ONE (2014)
EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
T. Kumai et al.
BRITISH JOURNAL OF CANCER (2013)
Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2013)
Quantification of EGFR autoantibodies in the amplification phenomenon of HER2 in breast cancer
Dorte Aa. Olsen et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2013)
EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
Teppei Yamada et al.
PLOS ONE (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Targeting the ERBB family in cancer: couples therapy
Niall Tebbutt et al.
NATURE REVIEWS CANCER (2013)
EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma
Patrick J. Schuler et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Vaccine provides new hope for patients with deadly brain cancer
[Anonymous]
FUTURE NEUROLOGY (2010)
Novel Immunogenic HLA-A*0201-restricted Epidermal Growth Factor Receptor-specific T-cell Epitope in Head and Neck Cancer Patients
Pedro A. Andrade Filho et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The biological properties of cetuximab
Bruno Vincenzi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
John H. Sampson et al.
SEMINARS IN IMMUNOLOGY (2008)
Autoantibodies in lung cancer:: possibilities for early detection and subsequent cure
C. J. Chapman et al.
THORAX (2008)
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2+ cancer patients
H Shomura et al.
BRITISH JOURNAL OF CANCER (2004)
Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients
H Shomura et al.
EUROPEAN JOURNAL OF CANCER (2004)
Share Paper
